Novel therapies show promise against myeloid leukemia
Researchers analyzed data on 553 patients treated with imatinib, finding that complete cytogenetic response significantly impacted long-term outcome. Patients with low Philadelphia chromosome positivity had higher chances of achieving a complete response.